Needham Maintains Buy on Jazz Pharmaceuticals, Lowers Price Target to $225
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia maintains a 'Buy' rating on Jazz Pharmaceuticals (NASDAQ:JAZZ) but lowers the price target from $226 to $225.

November 09, 2023 | 12:41 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Needham analyst maintains a 'Buy' rating on Jazz Pharmaceuticals but lowers the price target from $226 to $225.
The news is directly about Jazz Pharmaceuticals. The 'Buy' rating is maintained which is positive, but the price target is slightly lowered which might have a neutral to slightly negative impact on the stock in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100